EN DE

WuXi XDC Cayman Inc (2268) Fair Value & Analysis

Healthcare · HK · Market cap HK$74.1B (≈ $9.4B) · ISIN KYG9808A1058

What is WuXi XDC Cayman Inc really worth?

WX WuXi XDC Cayman Inc 2268 · HK
PriceHK$72.80
Fair ValueHK$19.46
Upside−73.3%
Quality52/100

A solid business, but trading 274% above our fair value of HK$19.46.

Watch WuXi XDC Cayman Inc for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free

Strengths

✓Highly profitable · 24.9% net margin
✓Low debt · generates free cash flow
✓Wide moat 78/100

Risks

!Mixed Growth (revenue 3y +81.7 %/yr)
!Mixed vs. peers (6/14)
!Weak on dividend: 3 out of 100
Evidence: High Range HK$12.34 – HK$32.36

Fair value as of: Sep 5, 2026

From 26 valuation models · updated today

Share price +34.3% over the past month.

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

What matters now

  • The price sits above even our optimistic bull case (HK$32.36). The favourable scenario is already priced in.
  • The model range is unusually wide (HK$12.34 to HK$32.36). The outcome hinges heavily on assumptions, so read the point estimate with caution.
  • Solid but not exceptional quality (52/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (3 years)

HK$85.10 HK$12.98 Fair Value HK$19.46 Nov 2023 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 5, 2026.

How to read this chart

34‑month range HK$12.98 – HK$85.10 · fair‑value band HK$12.34 – HK$32.36 · the HK$72.80 price screens above the HK$19.46 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 5, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

WuXi XDC Cayman Inc (2268) currently trades at HK$72.80, while our model-based Fair Value estimate is HK$19.46, implying the stock looks roughly 274.1% overvalued today. The Quality Score stands at 52/100 (solid quality), in the Healthcare sector. Bull case: the Growth Earnings group reads highest at a median of HK$50.58 per share, and 0 of the 26 models we run sit above the HK$72.80 price. Bear case: the Asset-Based group reads lowest at HK$5.70, and 26 of the 26 models stay below the price. Evidence for this calculation is high.

Over the trailing twelve months, WuXi XDC Cayman Inc generated revenue of HK$5.9B at a net margin of 24.9%. Revenue grew 35.9% year over year. It earns a return on equity of 17.1%. The balance sheet holds a net cash position of HK$632M. Fundamentals as of Sep 5, 2026

Our scenario range runs from HK$12.34 (bear case) to HK$32.36 (bull case); at HK$72.80, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat. The share trades about 15% below its 52-week high and 71% above its 52-week low, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at −54% fair-value upside, at −73%, 2268 screens richer than that median.

Fair Value models

This estimate rests on fiscal year 2025 figures, and about 8 months have passed since. In that time the company retained roughly HK$0.3857 per share, which is 2.0 % of the fair value. The fair value deliberately does not add this in: the models value reported figures, not a projection.

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted, family-balanced blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small. Every input is real reported data, nothing guessed.

Note: the current price implies far more future growth than the conservative anchors of our models allow (base growth is deliberately capped, we do not regard such extreme rates as sustainable). Our models are not designed for expectations this high; that is why the individual models scatter extremely (HK$1.39 to HK$55.71). Read the values as a conservative anchor, not as a price target.
Model Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
FCF DCF HK$9.66 HK$14.52 HK$30.00 74
EPV HK$11.50 HK$13.22 HK$14.72 74
Growth DCF HK$9.16 HK$17.01 HK$29.87 73
All 26 models by family
DCF Models
FCF DCF HK$9.66 HK$14.52 HK$30.00 74
Owner Earnings HK$6.45 HK$13.16 HK$27.25 69
5Y Revenue Exit HK$7.51 HK$12.02 HK$21.45 68
5Y EBITDA Exit HK$11.49 HK$20.06 HK$36.89 70
5Y P/E Exit HK$14.82 HK$33.43 HK$59.09 65
10Y Revenue Exit HK$8.03 HK$15.94 HK$20.88 64
10Y EBITDA Exit HK$11.15 HK$24.50 HK$48.11 62
10Y P/E Exit HK$13.58 HK$31.67 HK$62.11 58
Earnings-Based
Graham-Dodd HK$7.99 HK$55.71 HK$78.17 61
Lynch FV HK$28.78 HK$41.11 HK$53.45 59
PEG = 1.0 HK$28.78 HK$41.11 HK$53.45 55
EPV HK$11.50 HK$13.22 HK$14.72 74
Dividend Discount
Gordon GGM HK$0.7900 HK$1.65 HK$2.61 64
DDM Multi-Stage HK$0.7900 HK$1.39 HK$1.73 64
Multiples
P/E Multiple HK$14.98 HK$19.97 HK$24.96 63
P/S Multiple HK$5.31 HK$7.07 HK$8.84 58
P/B Multiple HK$14.98 HK$19.97 HK$24.96 55
EV/EBIT HK$14.69 HK$19.19 HK$23.69 66
EV/EBITDA HK$11.75 HK$15.28 HK$18.80 67
EV/Revenue HK$6.14 HK$8.26 HK$10.38 54
Asset-Based
NCAV (Graham) HK$4.26 HK$5.70 HK$8.51 54
Growth DCF
Growth DCF HK$9.16 HK$17.01 HK$29.87 73
Rev-Margin DCF HK$8.17 HK$13.58 HK$24.93 67
Economic Profit
Residual Income HK$8.25 HK$10.85 HK$33.89 62
ROIC Compounder HK$14.76 HK$20.84 HK$25.89 70
Growth Earnings
Growth-Adj P/E HK$35.41 HK$50.58 HK$65.76 65

Widest divergence: Growth Earnings (HK$50.58) versus Dividend Discount (HK$1.39). Highest evidence: FCF DCF (74).

Notify me when 2268 reaches fair value

Put 2268 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Free, no payment details. Unsubscribe anytime in one click.

Key figures & financial health

P/E ratio 45.6 as of Jul 2, 2026
P/S ratio 11.4 P/E × margin
EPS (TTM) HK$0.5700 price ÷ EPS = P/E 45.6
Dividend yield 0.1% payout 18.7%
Net margin 24.9% FY2025
Return on equity 17.1% TTM
More key figures
Profitability
Return on assets (EBIT) 7.8% avg 5y
Operating margin 26.3% TTM
Growth
Revenue (TTM) HK$5.9B TTM
Revenue growth (YoY) +35.9% 3y avg +81.7%
EPS growth (YoY) +22.3%
Balance sheet & cash flow
Free cash flow HK$635M FY2025
Net cash HK$632M FY2025

Figures from reported company fundamentals · as of Sep 5, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 52/100

Of which business quality 53 · Market factors (momentum, volatility) 62

Profitability 54
Margins and returns on capital today
Quality Growth 57
Are margins and returns improving?
Cashflow 51
Earnings quality: real cash, not paper profit
Fin. Strength 86
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 54
Calm price path (market factor)
Momentum 65
Price trend over the last 3–12 months (market factor)
52W Momentum 68
Distance to the 52-week high (market factor)
Net Issuance 46
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

All values are scores from 0 to 100 (100 = best against fixed, research-based bands), not percentages. The three market factors (momentum, 52-week proximity, low volatility) are displayed but carry zero weight in the headline number: market sentiment is not a business property.

About the company

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally.

Full company description

WuXi XDC Cayman Inc., an investment holding company, operates as a contract research, development, and manufacturing organization in China, North America, Europe, and internationally. It engages in the discovery, research, development, and manufacture of the drug substances and drug products of antibody drug conjugates, bioconjugates, monoclonal antibody intermediates, and payload-linkers associated with bioconjugates. It also provides international sales contracting services. Additionally, the company engages in the research and development, manufacturing, and marketing of anti-tumor drugs. WuXi XDC Cayman Inc. has a strategic collaboration with Earendil Labs; and Akari Therapeutics. The company was founded in 2013 and is headquartered in Wuxi, China. WuXi XDC Cayman Inc. is a subsidiary of WuXi Biologics (Cayman) Inc. WuXi XDC Cayman Inc. operates as a subsidiary of WuXi Biologics (Cayman) Inc.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

WuXi XDC Cayman Inc reported revenue of 5.9B CNY in FY2025 versus 311M CNY in FY2021, a compound +109.1%/yr. Reported net income was 1.5B CNY in FY2025, compounding +127.9%/yr from FY2021. FY2021 was a trough year, so the rate overstates the trend.

Growth Quality 77/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2025)
HK$5.9B
Latest YoY
+46.7%
Avg. revenue growth/yr (3Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+81.7%
Avg. revenue growth/yr (18Y) ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+18.8%
Value creation/yr ⓘWe only publish this rate when it is defensible. Reason: rate outside our plausibility band
not computed
Revenue +109.1%/yr
FY21 311M CNY
FY22 990M CNY
FY23 2.1B CNY
FY24 4.1B CNY
FY25 5.9B CNY
Net income +127.9%/yr
FY21 54.9M CNY
FY22 156M CNY
FY23 284M CNY
FY24 1.1B CNY
FY25 1.5B CNY

2268 screens 274% overvalued. Compare with Thermo Fisher Scientific Inc →

Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
Share or link this analysis
𝕏 Post WhatsApp LinkedIn Reddit
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

WuXi XDC Cayman Inc · Fair Value
HK$19.46 −274%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "WuXi XDC Cayman Inc Fair Value". https://www.fairvalue-calculator.com/stock/2268

Earlier news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

Peer Group

Diagnostics & Research · 130 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 52 · Below median
Fair Value upside −73% · Bottom 25%
Return on equity (TTM) 17% · Top 25%
Return on assets 9% · Top 25%
Net margin (TTM) 25% · Top 25%
Operating margin (TTM) 26% · Top 25%
Revenue growth 36% · Top 25%
Dividend yield (TTM) 0.1% · Bottom 25%
Debt / equity 0.00× · Lower than 75% of peers

Valuation Multiples vs Diagnostics & Research median · lower = cheaper

P/E (TTM) 45.6× · Pricier than median
P/B 6.91× · Pricier than 75% of peers
P/S (TTM) 12.47× · Pricier than 75% of peers
P/FCF 14.9× · Pricier than median
EV/EBITDA 41.1× · Pricier than 75% of peers

Strength profile in five axes (Snowflake)

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE0 · sector 0
FUTURE100 · sector 30
PAST68 · sector 12
HEALTH100 · sector 96
DIVIDEND3 · sector 20

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Diagnostics & Research stocks, each showing price versus our Fair Value estimate (as of Sep 5, 2026).

Stock Price Fair Value vs Fair Value
Thermo Fisher Scientific Inc TMO $630.70 $308.19 −51%
Danaher Corporation DHR $215.68 $103.88 −52%
WuXi AppTec Co 2359 HK$189.30 HK$150.16 −21%
Lonza Group LONN CHF 576.60 CHF 259.80 −55%
IDEXX Laboratories, Inc IDXX $556.69 $255.77 −54%
Agilent Technologies, Inc A $149.93 $61.53 −59%
Waters Corporation WAT $416.15 $121.96 −71%
IQVIA Holdings IQV $236.66 $132.17 −44%
Illumina, Inc ILMN $215.59 $95.51 −56%
Mettler-Toledo International Inc MTD $1,419 $615.78 −57%

Compare WuXi XDC Cayman Inc with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screener Filter by region, size and sector Compare tool Two stocks side by side Extrinsic Value Calculator (Options) Splits an option premium into intrinsic and extrinsic (time) value. Peter Lynch Fair Value Formula & Calculator Apply Peter Lynch's fair value formula in seconds: fair P/E ≈ earnings growth (+ dividend) - free, with formula and example.

Frequently asked questions

Is WuXi XDC Cayman Inc (2268) overvalued or undervalued?
As of Sep 5, 2026, our model estimates a fair value of HK$19.46 versus a price of HK$72.80, about −73% upside (overvalued).
What is the fair value of 2268?
Our model-based fair value for WuXi XDC Cayman Inc is HK$19.46 (as of Sep 5, 2026), built from audited fundamentals. The current price: HK$72.80.
What is the quality score of 2268?
WuXi XDC Cayman Inc has a Quality Score of 52/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of WuXi XDC Cayman Inc (2268)?
WuXi XDC Cayman Inc reported trailing-twelve-month revenue of about HK$5.9B (latest available figure, as of Sep 5, 2026).
What is the net profit margin of 2268?
The net profit margin of WuXi XDC Cayman Inc is about 24.9%, meaning it keeps roughly 24.9% of revenue as net income. Based on the latest reported figures.
Does WuXi XDC Cayman Inc pay a dividend?
WuXi XDC Cayman Inc currently shows a dividend yield of about 0.15% relative to its recent price (as of Sep 5, 2026).
Free · no account needed

Watch WuXi XDC Cayman Inc in the live analysis

One click puts WuXi XDC Cayman Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.